Teva UK (Teva) has launched generic co-Beneldopa capsules in a variety of strengths. The company said that they are the first generic to reach the market.
Co-Beneldopa is a dopaminergic drug indicated for treatment of symptoms of parkinson’s disease. It is a generic version of Madopar (co- beneldopa) made by Roche.
It is available in the Teva 360 livery, which is designed to aid patient safety, in the strengths and at the prices as Co-beneldopa capsules 50mg / 12.5mg x 100 GBP5.36, Co-beneldopa capsules 100mg / 25mg x 100 GBP7.47 and Co-beneldopa capsules 200mg / 50mg x 100 GBP12.74.
Kim Innes, commercial director of Teva, said: “We’re delighted to be launching co-Beneldopa capsules. This product fits well with our range and strengthens our position as the UK’s leading generics supplier. It comes hot on the heels of diamorphine hydrochloride (HCL) powder for injection, oxcarbazepine tablets and topiramate tablets which were added to our product portfolio during the last quarter.
“At the moment over 50% of scripts are written by brand. If all scripts were written and dispensed generically the potential saving to the NHS would be over GBP341k annually.”